JP2006502117A - 抗腫瘍活性を上昇させるための化学療法薬物の組み合わせ - Google Patents

抗腫瘍活性を上昇させるための化学療法薬物の組み合わせ Download PDF

Info

Publication number
JP2006502117A
JP2006502117A JP2004521887A JP2004521887A JP2006502117A JP 2006502117 A JP2006502117 A JP 2006502117A JP 2004521887 A JP2004521887 A JP 2004521887A JP 2004521887 A JP2004521887 A JP 2004521887A JP 2006502117 A JP2006502117 A JP 2006502117A
Authority
JP
Japan
Prior art keywords
oxyalkylene
administered
cancer
treatment
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004521887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502117A5 (https=
Inventor
ルイス アール． ブカロ，
スニル スリーダラン，
Original Assignee
タイタン ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タイタン ファーマシューティカルズ インコーポレイテッド filed Critical タイタン ファーマシューティカルズ インコーポレイテッド
Publication of JP2006502117A publication Critical patent/JP2006502117A/ja
Publication of JP2006502117A5 publication Critical patent/JP2006502117A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004521887A 2002-07-17 2003-07-11 抗腫瘍活性を上昇させるための化学療法薬物の組み合わせ Pending JP2006502117A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39666702P 2002-07-17 2002-07-17
PCT/US2003/022181 WO2004006909A1 (en) 2002-07-17 2003-07-11 Combination of chemotherapeutic drugs for increasing antitumor activity

Publications (2)

Publication Number Publication Date
JP2006502117A true JP2006502117A (ja) 2006-01-19
JP2006502117A5 JP2006502117A5 (https=) 2006-07-27

Family

ID=30116048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004521887A Pending JP2006502117A (ja) 2002-07-17 2003-07-11 抗腫瘍活性を上昇させるための化学療法薬物の組み合わせ

Country Status (12)

Country Link
US (1) US20060089410A1 (https=)
EP (1) EP1534262A1 (https=)
JP (1) JP2006502117A (https=)
KR (1) KR20050040907A (https=)
CN (1) CN1681489A (https=)
AU (1) AU2003251942A1 (https=)
CA (1) CA2492175A1 (https=)
IL (1) IL166214A0 (https=)
MX (1) MXPA05000555A (https=)
NZ (1) NZ537759A (https=)
WO (1) WO2004006909A1 (https=)
ZA (1) ZA200500418B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017125021A (ja) * 2007-07-30 2017-07-20 アーディア・バイオサイエンシーズ・インコーポレイテッドＡｒｄｅａ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
JP2021523090A (ja) * 2018-03-09 2021-09-02 科済生物医薬（上海）有限公司Ｃａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．，Ｌｔｄ． 腫瘍を治療するための方法および組成物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
CA2626679C (en) * 2005-11-04 2011-08-16 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
CN102482249B (zh) 2009-07-08 2016-06-08 德米拉(加拿大)公司 用于治疗皮肤病症或疾病状态的tofa类似物
US20110153343A1 (en) 2009-12-22 2011-06-23 Carefusion 303, Inc. Adaptable medical workflow system
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20190046513A1 (en) * 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
WO2019196111A1 (zh) * 2018-04-13 2019-10-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302349B1 (en) * 1987-07-30 1993-09-29 Bar Ilan University Biologically active carboxylic acid esters

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017125021A (ja) * 2007-07-30 2017-07-20 アーディア・バイオサイエンシーズ・インコーポレイテッドＡｒｄｅａ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
JP2021523090A (ja) * 2018-03-09 2021-09-02 科済生物医薬（上海）有限公司Ｃａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．，Ｌｔｄ． 腫瘍を治療するための方法および組成物
US12186343B2 (en) 2018-03-09 2025-01-07 Crage Medical Co., Limited Method and composition for treating tumors
JP2025016535A (ja) * 2018-03-09 2025-02-04 クレージュ メディカル カンパニー，リミテッド 腫瘍を治療するための方法および組成物

Also Published As

Publication number Publication date
CA2492175A1 (en) 2004-01-22
AU2003251942A1 (en) 2004-02-02
WO2004006909A1 (en) 2004-01-22
US20060089410A1 (en) 2006-04-27
EP1534262A1 (en) 2005-06-01
ZA200500418B (en) 2006-10-25
KR20050040907A (ko) 2005-05-03
CN1681489A (zh) 2005-10-12
NZ537759A (en) 2006-10-27
IL166214A0 (en) 2006-01-15
MXPA05000555A (es) 2005-04-28

Similar Documents

Publication Publication Date Title
Gao et al. Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis
JP2006502117A (ja) 抗腫瘍活性を上昇させるための化学療法薬物の組み合わせ
Liu et al. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer
Chen et al. Quercetin suppresses human glioblastoma migration and invasion via GSK3β/β-catenin/ZEB1 signaling pathway
Wang et al. Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil
Khodakarami et al. The molecular biology and therapeutic potential of Nrf2 in leukemia
Shin et al. A curcumin derivative hydrazinobenzoylcurcumin suppresses stem‐like features of glioblastoma cells by targeting Ca2+/calmodulin‐dependent protein kinase II
Hurmath et al. Sevoflurane and thiopental preconditioning attenuates the migration and activity of MMP-2 in U87MG glioma cells
JP2016528217A (ja) 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
Chen et al. Investigating the synergy of Shikonin and Valproic acid in inducing apoptosis of osteosarcoma cells via ROS-mediated EGR1 expression
CN118161618A (zh) 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途
Zhao et al. Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
Liu et al. Solamargine improves the therapeutic efficacy of anti-PD-L1 in lung adenocarcinoma by inhibiting STAT1 activation
Li et al. AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer
CN102688493A (zh) 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用
US20200261393A1 (en) Treatment of cancer with combinations of agents
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
TW202034919A (zh) 西奧羅尼用於小細胞肺癌的治療
CN115105603B (zh) MCL-1抑制剂和BCL-xL抑制剂在制备治疗实体肿瘤药物中的应用
KR101471498B1 (ko) 암의 치료를 위한 화합물 및 방법
CN102215833B (zh) 苯醌衍生物e3330联合化疗剂用于治疗癌症和血管生成
EP4452275B1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
Lin et al. Auranofin and ICG-001 emerge synergistic anti-tumor effect on canine breast cancer by inducing apoptosis via mitochondrial pathway
US10550130B2 (en) Benzo-thiazolo-imidazole compounds and uses thereof
EP4684788A1 (en) Pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100202